A novel SATB1 binding site in the BCL2 promoter region possesses transcriptional regulatory function

Journal of Biomedical Research

Volumn 24, Issue 6, 2010, Pages 452-459

  Gong, Feiran ^a   Sun, Luan ^a   Sun, Yujie ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

BCL2; Promoter; Special AT rich sequence binding protein 1; Transcriptional regulation

Indexed keywords

BINDING PROTEIN; LUCIFERASE; PROTEIN BCL 2; SPECIAL AT RICH SEQUENCE BINDING PROTEIN 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BIOINFORMATICS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE ACTIVITY; GENE MUTATION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; REPORTER GENE; TRANSCRIPTION REGULATION;

EID: 78650657102     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1674-8301(10)60060-7     Document Type: Article

References (36)

1. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348:334-336.
2. Deng X, Gao F, May WS Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood 2003, 102:3179-3185.
3. Zhang W, Pantschenko AG, McCarthy MB, Gronowicz G Bone-targeted overexpression of Bcl-2 increases os-teoblast adhesion and differentiation and inhibits mineralization in vitro. Calcif Tissue Int 2007, 80:111-122.
4. Adams JM, Huang DC, Puthalakath H, Bouillet P, Vairo G, Moriishi K, et al. Control of apoptosis in hematopoi-etic cells by the Bcl-2 family of proteins. Cold Spring Harb Symp Quant Biol 1999, 64:351-358.
5. Hara T, Omura-Minamisawa M, Kang Y, Cheng C, In-oue T Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed. Int J Radiat Oncol Biol Phys 2008, 71:1485-1495.
6. Young RL, Korsmeyer SJ A negative regulatory element in the bcl-2 5'-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 1993, 13:3686-3697.
7. Miyashita T, Harigai M, Hanada M, Reed JC Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994, 54:3131-3135.
8. Heckman CA, Mehew JW, Ying GG, Introna M, Golay J, Boxer LM A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. J Biol Chem 2000, 275:6499-6508.
9. Schiavone N, Rosini P, Quattrone A, Donnini M, Lapucci A, Citti L, et al. A conserved AU-rich element in the 3' untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. FASEB J 2000, 14:174-184.
10. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001, 20:240-251.
11. Heckman CA, Mehew JW, Boxer LM NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. On-cogene 2002, 21:3898-3908.
12. Donnini M, Lapucci A, Papucci L, Witort E, Jacquier A, Brewer G, et al. Identification of TINO: a new evo-lutionarily conserved BCL-2 AU-rich element RNA-binding protein. J Biol Chem 2004, 279:20154-20166.
13. Ma C, Zhang J, Durrin LK, Lv J, Zhu D, Han X, et al. The BCL2 major breakpoint region (mbr) regulates gene expression. Oncogene 2007, 26:2649-2657.
14. Chen HM, Boxer LM Pi 1 binding sites are negative regulators of bcl-2 expression in pre-B cells. Mol Cell Biol 1995, 15:3840-3847.
15. Wilson BE, Mochon E, Boxer LM Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996, 16:5546-5556.
16. Perillo B, Sasso A, Abbondanza C, Palumbo G 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 2000, 20:2890-2901.
17. Lang G, Gombert WM, Gould HJ A transcriptional regulatory element in the coding sequence of the human Bcl-2 gene. Immunology 2005, 114:25-36.
18. Zhang J, Ma C, Han X, Durrin LK, Sun Y The bcl-2 major breakpoint region (mbr) possesses transcriptional regulatory function. Gene 2006, 379:127-131.
19. Smith MD, Ensor EA, Coffin RS, Boxer LM, Latchman DS Bcl-2 transcription from the proximal P2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor. J Biol Chem 1998, 273:16715-16722.
20. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988, 7:123-131.
21. Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell 1992, 70:631-645.
22. Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T SATB1 targets chromatin remodelling to regulate genes over long distances. Nature 2002, 419:641-645.
23. Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev 2000, 14:521-535.
24. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008, 452:187-193.
25. Wen J, Huang S, Rogers H, Dickinson LA, Kohwi-Shigematsu T, Noguchi CT SATB1 family protein expressed during early erythroid differentiation modifies globin gene expression. Blood 2005, 105:3330-3339.
26. Fujii Y, Kumatori A, Nakamura M SATB1 makes a complex with p300 and represses gp91(phox) promoter activity. Microbiol Immunol 2003, 47:803-811.
27. Blagosklonny MV Sequential activation and inacti-vation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 2002, 21:6249-6254.
28. Demidenko ZN, Blagosklonny MV Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004, 64:3653-3660.
29. Gstaiger M, Knoepfel L, Georgiev O, Schaffner W, Hovens CM A B-cell coactivator of octamer-binding transcription factors. Nature 1995, 373:360-362.
30. Belsham DD, Mellon PL Transcription factors Oct-1 and C/EBPbeta (CCAAT/enhancer-binding proteinbeta) are involved in the glutamate/nitric oxide/cyclic-guanosine 5'-monophosphate-mediated repression of mediated repression of gonadotropin-releasing hormone gene expression. Mol Endocrinol 2000, 14:212-228.
31. Zabel MD, Wheeler W, Weis JJ, Weis JH Yin Yang 1, Oct1, and NFAT-4 form repeating, cyclosporin-sensitive regulatory modules within the murine CD21 intronic control region. J Immunol 2002, 168:3341-3350.
32. Mordvinov VA, Schwenger GT, Fournier R, De Boer ML, Peroni SE, Singh AD, et al. Binding of YY1 and Oct1 to a novel element that downregulates expression of IL-5 in human T cells. J Allergy Clin Immunol 1999, 103:1125-1135.
33. Izon DJ, Rozenfeld S, Fong ST, Komuves L, Largman C, Lawrence HJ Loss of function of the homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive thymocytes. Blood 1998, 92:383-393.
34. Funakoshi S, Ezaki T, Kong J, Guo RJ, Lynch JP Repression of the desmocollin 2 gene expression in human colon cancer cells is relieved by the homeodomain transcription factors Cdx1 and Cdx2. Mol Cancer Res 2008, 6:1478-1490.
35. Shimada T, Koike T, Yamagata M, Yoneda M, Hirai-shi H Regulation of TFF3 expression by homeodomain protein CDX2. Regul Pept 2007, 140:81-87.
36. Duan H, Xiang H, Ma L, Boxer LM Functional longrange interactions of the IgH 3' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells. Oncogene 2008, 27:6720-6728.